🟢 NeOnc Technologies Holdings is trading 6.65% up after scheduling FDA End-of-Phase 1 meeting for NEO212

NeOnc Technologies Holdings is trading 6.65% up at $3.37 after an in-person FDA meeting for NEO212 was scheduled for November 17, 2026.

• The company plans to seek feedback on patient population, trial design, endpoints and dose selection.
• The meeting is scheduled, not an FDA endorsement of a trial design or approval pathway.
• Coverage also reported pre-market trading at $3.36, up 6.33%; no live volume figure was available, so intraday activity cannot be assessed.